VENORUTON Intent film -coated tablets, 100 pcs

Instructions for use for VENORUTON Intent film -coated tablets, 100 pcs

Detailed instructions for VENORUTON Intent film -coated tablets, 100 pcs

Field of use

Venoruton Intensive film -coated tablets (pack size: 100 pc) treats vein disorders. It promotes blood circulation, reduces pain and swelling on ankles and legs, can alleviate symptoms such as tension and tingling and the feeling of heavy in the legs.

In chronic vein disorders, Venoruton intensive film -coated tablets (pack size: 100 pcs) targeted medical help.

The refined natural active ingredient oxerutin seals the venous walls and strengthened from the inside, which means that less water can escape into the surrounding tissue (edema).

The pain is noticeably relieved and aggravation is prevented. This also applies to follow-up and side effects of chronic vein insufficiency, varicose and post-thrombotic syndromes.

Venoruton Intensive film -coated tablets (pack size: 100 pc) also work against vein disorders during pregnancy from the 4th month. It is also a protective medication for radiation treatment and diabetic microangiopathies.

Mode of action

Venoruton Intent film -coated tablets (pack size: 100 pcs) helps with venous weakness

• regulates the permeability of the weakened vein walls, which means that less liquid can escape from the fine vessels into the surrounding tissue
• Edema and swelling can be reduced
• the microcirculation is also promoted

Active ingredients / ingredients / ingredients

1 Venoruton Intent film -coated tablets (pack size: 100 pc) contains:

• Hydroxyethyl rutosides (oxerutin) 500mg

The other ingredients are: polyacrylate dispersion 30%; Talc; Copovidon; Gelborange S, aluminum salt; Magnesium stair; Titanium dioxide; Macrogol 6000.

Contradictions

• The medicine must not be taken,
  • if you are allergic to the active ingredient poly (O-2 -hydroxyethyl) rutoside or one of the other components of this medicine.

dosage

• Always take this medicine exactly as described or exactly after the agreement made with your doctor or pharmacist. Ask your doctor or pharmacist if you are not sure.
• The recommended dose is 1 film-coated tablet twice a day.

• Duration of the application
  • The duration of the intake depends on the symptoms. Basically there is no time limit for the duration of use. If the symptoms are stopped, treatment can be continued over a longer period of time after medical consultation.
  • Success depends largely on the consistent attention of the prescribed dosage and the duration of treatment.

• If you have taken a larger amount than you should
  • No cases of poisoning are known, so no measures are required.

• If you have forgotten the intake
  • Do not take the double amount if you have forgotten the prior intake.

• If you cancel the intake
  • If you interrupt the treatment or end the intake prematurely, you must expect the desired effect to not occur or the clinical picture deteriorates again. Therefore, please consult your doctor if you want to end or interrupt the treatment.

• If you have any further questions about taking this medicine, please contact your doctor or pharmacist.

Taking

• Please take the film -coated tablets during meals or immediately afterwards Unzukaut with some liquid.

Patient information

• Please take the film -coated tablets during meals or immediately afterwards Unzukaut with some liquid.
• Notice
  • With this film -coated tablet, the active ingredient is stored in a carrier structure. In individual cases, it can happen that the carrier structure is not broken down in the intestine and therefore appears in the chair. However, the active ingredient output from the film -coated tablets in the body was not affected.

• Wateriness and ability to operate machines
  • The medicine has no influence on the ability to use and the ability to use machines.

Pregnancy

• If you are pregnant or breastfeed, or if you suspect that you are pregnant or intend to become pregnant, ask your doctor or pharmacist for advice before using this drug.
• Pregnancy
  • Since there is only inadequate experiences in the first months of pregnancy, you should only take the medicine with the desire to have children and during pregnancy after consultation with your doctor.
• Breastfeeding
  • Please speak to your doctor about this. There are no examinations in humans to transition the active ingredient to breast milk. Traces of the active ingredient found during animal experiments in breast milk are not of clinical importance and are therefore probably also harmless to the human infant.

Hints

Miscellaneous

- The individual quantity and daily amount of the drug can be increased without further ado, if necessary in special cases.